Robert Jotte, MD
Hematology & Oncology · Lone Tree, CONPI 1669457032
Payments from drug & device makers
Across 2,061 payments — averaging $4560.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$1.4M
- Amgen$1.3M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Genentech, Inc.$908K
- AstraZeneca$895K
- Eli Lilly$608K
- plus $3.2M from 28 others
Across 34 payments — averaging $740.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$12K
- Janssen Scientific Affairs, LLC$8K
- Bristol Myers Squibb$5K
- Eli Lilly$100
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 352 | $1,407,699 |
| Amgen | 34 | $1,286,111 |
| E.r. Squibb & Sons, L.L.C. | 69 | $1,134,845 |
| Genentech, Inc. | 162 | $907,924 |
| AstraZeneca | 29 | $894,783 |
| Eli Lilly | 29 | $607,783 |
| Bayer | 42 | $586,300 |
| Seagen Inc. | 330 | $393,733 |
| Pfizer | 276 | $360,883 |
| Incyte Corporation | 113 | $274,492 |
| Janssen Research & Development, LLC | 112 | $257,722 |
| Puma Biotechnology, Inc. | 50 | $251,213 |
| GSK | 53 | $171,874 |
| Novartis | 6 | $166,715 |
| F. Hoffmann-la Roche AG | 43 | $158,594 |
| Beigene, Ltd. | 11 | $128,016 |
| Merck | 11 | $107,071 |
| Beone Medicines Ltd. | 6 | $88,524 |
| EMD Serono, Inc. | 160 | $83,726 |
| AbbVie | 9 | $47,881 |
| Genentech USA, Inc. | 29 | $45,954 |
| Janssen Scientific Affairs, LLC | 110 | $10,100 |
| Lilly USA, LLC | 1 | $7,860 |
| Chugai Pharmaceutical Co., Ltd. | 5 | $6,423 |
| Ipsen Biopharmaceuticals, Inc | 3 | $3,189 |
| EMD Serono Research & Development Institute, Inc. | 3 | $3,189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,908 |
| Jazz Pharmaceuticals Inc. | 1 | $1,590 |
| Novocure Inc. | 2 | $1,272 |
| Astrazeneca UK Limited | 5 | $975 |
| Johnson & Johnson | 1 | $134 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Telix Pharmaceuticals | 1 | $20 |
How this compares
$9,398,550 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Lone Tree
- David AndorskyBoulder$31.5M
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Allen CohnDenver$13.5M
- Elaine LamAurora$12.6M
- Robert RifkinDenver$11.3M
- Daniel PollyeaAurora$9.4M
- Henning SchadeDenver$9M
- Manali KamdarAurora$8.9M
- Steven SchusterFort Collins$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.